Prelude Therapeutics (PRLD) Return on Sales (2024 - 2026)

Prelude Therapeutics (PRLD) posted Return on Sales of 0.08% for Q1 2026, down 134.57% sequentially from 0.03% in Q4 2025.

Prelude Therapeutics (PRLD) Return on Sales (2024 - 2026) Analysis & Trends

Prelude Therapeutics has reported Return on Sales for 3 years, with the latest figure at 0.08% in Q1 2026.

Quarterly Return on Sales changed N/A year-over-year to 0.08% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.09% (changed N/A YoY) and the FY2025 annual result came in at 0.26%, up 20.0% from the prior year.
Return on Sales retreated to 0.08% in Q1 2026 per PRLD's latest filing, from 0.03% in the prior quarter.
Over five years, Return on Sales peaked at 0.03% in Q4 2025 and troughed at 0.25% in Q3 2024.
A 3-year average of 0.1% and a median of 0.08% in 2026 frame the typical range for Return on Sales.
The widest YoY moves for Return on Sales: up 19 bps in 2025, down 5 bps in 2025.
Over 3 years, Return on Sales stood at 0.09% in 2024, then surged by 63 bps to 0.03% in 2025, then slumped by 135 bps to 0.08% in 2026.
According to Business Quant data, Return on Sales over the past three periods registered 0.08%, 0.03%, and 0.06% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.00%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	0.00%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.00%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	0.00%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.00%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	0.00%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.00%
10	Prelude Therapeutics	442.91 Mn	162.28 Mn	-	-0.09%

Download Data